ss1(dsfv)pe38
mAbexperimentalADC
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2000 (NCT00024687)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adenocarcinoma · Phase 1
- Adenocarcinoma of Lung · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- Head and Neck Neoplasms · Phase 1
- Lung Neoplasms · Phase 1
- Mesothelioma · Phase 1/Phase 2
- Mesothelioma, Malignant · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- MesothelinBINDING AGENT
MSLN binding agent
- MesothelinINHIBITOR
MSLN inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Pseudomonas exotoxin A
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109516 ↗
Also known as
- ss1(dsfv)pe38
- ss1(dsfv)-pe38
- ss1(dsfv)-pe38
- ss1p
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01362790 | Phase 1/Phase 2 (Phase 2) | May 11, 2011 | National Cancer Institute (NCI) |
| NCT01051934 | Phase 1 | Dec 29, 2009 | National Cancer Institute (NCI) |
| NCT01445392 | Phase 1 | Nov 13, 2007 | National Cancer Institute (NCI) |
| NCT00066651 | Phase 1 | Jul 1, 2003 | National Cancer Institute (NCI) |
| NCT00024674 | Phase 1 | Feb 1, 2001 | Insys Therapeutics Inc |
| NCT00006981 | Phase 1 | Dec 1, 2000 | National Cancer Institute (NCI) |
| NCT00024687 | Phase 1 | Nov 1, 2000 | Insys Therapeutics Inc |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 5 | 5 | 2 | 2000 |
| Insys Therapeutics Inc | For profit | 2 | 2 | 1 | 2000 |
2 organizations
Page 1 / 1